JP2019147764A - Preservation liquid for semen and semen transport method using same - Google Patents
Preservation liquid for semen and semen transport method using same Download PDFInfo
- Publication number
- JP2019147764A JP2019147764A JP2018033638A JP2018033638A JP2019147764A JP 2019147764 A JP2019147764 A JP 2019147764A JP 2018033638 A JP2018033638 A JP 2018033638A JP 2018033638 A JP2018033638 A JP 2018033638A JP 2019147764 A JP2019147764 A JP 2019147764A
- Authority
- JP
- Japan
- Prior art keywords
- semen
- sperm
- solution according
- preservation solution
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000582 semen Anatomy 0.000 title claims abstract description 181
- 238000004321 preservation Methods 0.000 title claims abstract description 15
- 239000007788 liquid Substances 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 23
- 230000019100 sperm motility Effects 0.000 claims abstract description 52
- 230000030609 dephosphorylation Effects 0.000 claims abstract description 35
- 239000003112 inhibitor Substances 0.000 claims abstract description 33
- 239000007789 gas Substances 0.000 claims abstract description 19
- 239000002480 mineral oil Substances 0.000 claims abstract description 11
- 235000010446 mineral oil Nutrition 0.000 claims abstract description 11
- 239000011261 inert gas Substances 0.000 claims abstract description 8
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 75
- 239000003761 preservation solution Substances 0.000 claims description 50
- 238000003860 storage Methods 0.000 claims description 50
- 239000000243 solution Substances 0.000 claims description 38
- 238000006209 dephosphorylation reaction Methods 0.000 claims description 29
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 12
- 229910052786 argon Inorganic materials 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 9
- 239000011684 sodium molybdate Substances 0.000 claims description 8
- 235000015393 sodium molybdate Nutrition 0.000 claims description 8
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 claims description 8
- 230000003204 osmotic effect Effects 0.000 claims description 6
- 239000011775 sodium fluoride Substances 0.000 claims description 6
- 235000013024 sodium fluoride Nutrition 0.000 claims description 6
- 238000003879 sperm preservation Methods 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 5
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical group CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 claims description 3
- 102000013563 Acid Phosphatase Human genes 0.000 claims description 3
- 108010051457 Acid Phosphatase Proteins 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 229940122907 Phosphatase inhibitor Drugs 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229940122720 Alkaline phosphatase inhibitor Drugs 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000282898 Sus scrofa Species 0.000 claims description 2
- 229940076850 Tyrosine phosphatase inhibitor Drugs 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 238000010257 thawing Methods 0.000 description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 238000005259 measurement Methods 0.000 description 14
- 230000009027 insemination Effects 0.000 description 11
- 230000004899 motility Effects 0.000 description 11
- 239000011550 stock solution Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 230000035899 viability Effects 0.000 description 10
- 244000144972 livestock Species 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 244000309464 bull Species 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 238000007427 paired t-test Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 238000010162 Tukey test Methods 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000015165 citric acid Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 229910001882 dioxygen Inorganic materials 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940127334 Dephosphorylation Inhibitors Drugs 0.000 description 3
- 238000001061 Dunnett's test Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- -1 female Chemical compound 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- 241000405961 Scomberomorus regalis Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 108010046016 Peanut Agglutinin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 1
- 229960003807 dibekacin Drugs 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000006892 negative regulation of dephosphorylation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WRMXOVHLRUVREB-UHFFFAOYSA-N phosphono phosphate;tributylazanium Chemical compound OP(O)(=O)OP([O-])([O-])=O.CCCC[NH+](CCCC)CCCC.CCCC[NH+](CCCC)CCCC WRMXOVHLRUVREB-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920006327 polystyrene foam Polymers 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AVPCPPOOQICIRJ-UHFFFAOYSA-L sodium glycerol 2-phosphate Chemical compound [Na+].[Na+].OCC(CO)OP([O-])([O-])=O AVPCPPOOQICIRJ-UHFFFAOYSA-L 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
本発明は、精液用保存液、及びそれを用いた精液輸送方法に関するものである。 The present invention relates to a semen preservation solution and a semen transport method using the same.
人工授精は、ヒトの不妊治療だけでなく、優良家畜の生産、品種改良、伝染性疾病の予防等の観点から普及している。特に家畜生産分野における人工授精の普及率は、ウシでほぼ100%、ブタでは約40%と非常に高い(非特許文献1)。 Artificial insemination is popular not only from the treatment of infertility in humans but also from the viewpoints of producing excellent livestock, breeding, and prevention of infectious diseases. In particular, the penetration rate of artificial insemination in the field of livestock production is very high at approximately 100% for cattle and approximately 40% for pigs (Non-patent Document 1).
家畜の人工授精用精液を製造及び供給する家畜人工授精所等は、一般的に、顕微鏡や自動細胞解析装置等を用いて比較的簡便に検査が可能である精子運動性または生存性を、人工授精用精液の製品品質の合格基準として定めている。凍結精液を製造する際は凍結融解後の精子運動性または生存性が一定以上の製品を、凍結しない液状精液を製造する際は精液を希釈液で希釈及び冷却した後の精子運動性または生存性が一定以上の製品を、合格として市場に供給している。 In general, livestock artificial insemination laboratories that produce and supply semen for artificial insemination of livestock have artificial sperm motility or viability that can be examined relatively easily using a microscope, an automatic cell analyzer, etc. Established as an acceptable standard for product quality of semen for insemination. When producing frozen semen, sperm motility or survival after freezing and thawing after diluting and cooling semen with diluted solution when producing semen motility or survival beyond a certain level after freezing and thawing Supplies a certain number of products to the market as acceptable.
一般的に、家畜等の哺乳動物の人工授精用精液の製造施設は、種畜を繋養する畜舎に隣接している。精液は、採取後直ちに製造施設内において希釈液で希釈及び冷却され、冷蔵または凍結保存されることで精子の代謝反応が遅延し、運動性及び生存性、ひいては人工授精による受胎性が保持されると考えられている。凍結精液の品質を向上させるため、人工授精ストロー(特許文献1)や凍結時の希釈液の改良(特許文献2)が行われている。 In general, a facility for producing semen for artificial insemination of mammals such as livestock is adjacent to a barn for feeding seedstock. Semen is diluted and cooled with diluent in the production facility immediately after collection, and refrigeration or cryopreservation delays sperm metabolic reaction, maintaining motility and viability, and thus fertility by artificial insemination. It is believed that. In order to improve the quality of frozen semen, artificial insemination straws (Patent Document 1) and dilution liquids during freezing (Patent Document 2) have been improved.
しかしながら、一度に多数の種畜の精液を取り扱う場合や畜舎から遠隔地に製造設備を持つ施設を有する場合など、精液を採取した後、直ちに冷却または凍結処理しない場合の精液保存技術及び輸送技術は十分に確立していない状況である。 However, semen storage technology and transport technology are not sufficient when semen is collected and not immediately cooled or frozen after handling semen from a large number of breeding animals at one time or having facilities with production facilities in a remote location from a barn. The situation has not been established.
つまり、家畜等の哺乳動物の精液は、pH緩衝剤や糖類を含む精液用保存液を添加して保存すると、採精直後の精子よりも著しく精子運動性が低下する。また、精液は輸送によるストレスで精子運動性及び生存性が低下する。そのため、従来の精液用保存液及びそれを用いた輸送方法では、精子の運動性や生存性低下を防ぐことに関して、十分な効果をえることができていなかった。 That is, when semen from mammals such as livestock is stored with a semen preservation solution containing a pH buffer or saccharide, the sperm motility is significantly lower than that immediately after semen collection. In addition, sperm motility and viability decrease due to stress due to transport. For this reason, the conventional semen preservation solution and the transport method using the same have not been able to provide a sufficient effect for preventing sperm motility and viability reduction.
本発明の課題は、人工授精に用いる高品質の精液を、遠隔地に輸送する為の精液用保存液及び精液輸送方法を提供することである。 An object of the present invention is to provide a semen preservation solution and a semen transport method for transporting high-quality semen used for artificial insemination to a remote place.
本発明者は、高品質の精液を安定的に供給するために、精液保存時に観察される精子の運動性低下を防ぐ精液用保存液の検討を行ってきた。 In order to stably supply high-quality semen, the present inventor has studied a semen preservation solution that prevents a decrease in sperm motility observed during semen preservation.
精液を保存・輸送に伴う精子代謝の進行や酸化ストレスに焦点を当てて検討したところ、タンパク質の脱リン酸化阻害剤を精液用保存液に添加することで、精子の運動性を高い水準で維持して保存・輸送することが可能となることを見出した。 We focused on sperm metabolism and oxidative stress associated with storage and transport of semen. By adding a protein dephosphorylation inhibitor to the semen preservation solution, sperm motility was maintained at a high level. And found that it can be stored and transported.
また、保存容器の空気層を、水素ガス、窒素ガス、アルゴンガス、ミネラルオイル等の物質に置き換えることで、輸送後の精子運動性だけでなく、輸送後に作製した凍結精液の品質が向上することを見出し、本発明に到った。 In addition, by replacing the air layer of the storage container with substances such as hydrogen gas, nitrogen gas, argon gas, mineral oil, etc., not only the sperm motility after transport but also the quality of frozen semen prepared after transport should be improved. The present invention was found.
本発明は、以下の発明を包含する。
[1] タンパク質の脱リン酸化阻害剤を含有することを特徴とする、精液用保存液。
[2] 前記精液が、哺乳動物由来の精液である、[1]に記載の精液用保存液。
[3] 前記脱リン酸化阻害剤が、前記精液中に含まれる精子タンパク質の脱リン酸化を阻害する阻害剤である、[1]又は[2]に記載の精液用保存液。
[4] 前記精子タンパク質が、精子の運動性に関連し、SDS−PAGEで求められる質量が50〜100キロダルトン(kDa)のタンパク質である、[3]に記載の精液用保存液。
[5] 前記脱リン酸化阻害剤が、酸性ホスファターゼ阻害剤、アルカリホスファターゼ阻害剤又はチロシンホスファターゼ阻害剤である、[1]〜[4]のいずれかに記載の精液用保存液。
[6] 前記脱リン酸化阻害剤が、イミダゾール、フッ化ナトリウム又はモリブデン酸ナトリウムである、[1]〜[5]のいずれかに記載の精液用保存液。
[7] 前記脱リン酸化阻害剤の含有量が、1〜100mMである、[1]〜[6]のいずれかに記載の精液用保存液。
[8] 精子のエネルギー源となる糖をさらに含有する、[1]〜[7]のいずれかに記載の精液用保存液。
[9] 前記糖が、グルコース、フルクトース、スクロース、ラクトース、ラフィノース、フルクトオリゴ糖、イソマルトオリゴ糖、ゲンチオオリゴ糖、又はガラクトオリゴ糖である、[8]に記載の精液用保存液。
[10] 浸透圧計(オズモメーター)を用いて測定される浸透圧が、230〜400mmol/kgである、[1]〜[9]のいずれかに記載の精液用保存液。
[11] 緩衝剤をさらに含有する、[1]〜[10]のいずれかに記載の精液用保存液。
[12] 緩衝剤が、トリス(ヒドロキシメチル)アミノメタン又はクエン酸である、[1]〜[11]のいずれかに記載の精液用保存液。
[13] 前記哺乳動物が、ウシ、水牛、ブタ、ヤギ、ウマ又はヒツジである、[2]〜[12]のいずれかに記載の精液用保存液。
[14] 精液を含有する、[1]〜[13]のいずれかに記載の精液用保存液からなる、精液含有保存液。
[15] 前記精液が、凍結保存した精液を融解してなる精液である、[14]に記載の精液含有保存液。
[16] [14]に記載の精液含有保存液を、ミネラルオイルと接触させた状態で輸送することを特徴とする、精液輸送方法。
[17] [14]に記載の精液含有保存液を、不活性ガスを含有する気体と接触させ、酸素体積比が20.1%以下となる状態で輸送することを特徴とする、精液輸送方法。
[18] 前記不活性ガスが、水素ガス、窒素ガス又はアルゴンガスである、[17]に記載の精液輸送方法。
The present invention includes the following inventions.
[1] A semen preservation solution comprising a protein dephosphorylation inhibitor.
[2] The semen preservation solution according to [1], wherein the semen is a semen derived from a mammal.
[3] The semen preservation solution according to [1] or [2], wherein the dephosphorylation inhibitor is an inhibitor that inhibits dephosphorylation of a sperm protein contained in the semen.
[4] The semen preservation solution according to [3], wherein the sperm protein is a protein having a mass of 50 to 100 kilodaltons (kDa) that is related to sperm motility and is determined by SDS-PAGE.
[5] The semen preservation solution according to any one of [1] to [4], wherein the dephosphorylation inhibitor is an acid phosphatase inhibitor, an alkaline phosphatase inhibitor, or a tyrosine phosphatase inhibitor.
[6] The semen preservation solution according to any one of [1] to [5], wherein the dephosphorylation inhibitor is imidazole, sodium fluoride, or sodium molybdate.
[7] The semen preservation solution according to any one of [1] to [6], wherein the content of the dephosphorylation inhibitor is 1 to 100 mM.
[8] The semen preservation solution according to any one of [1] to [7], further containing a sugar that is an energy source for sperm.
[9] The semen preservation solution according to [8], wherein the sugar is glucose, fructose, sucrose, lactose, raffinose, fructooligosaccharide, isomaltooligosaccharide, gentio-oligosaccharide, or galactooligosaccharide.
[10] The semen preservation solution according to any one of [1] to [9], wherein the osmotic pressure measured using an osmometer (Osmometer) is 230 to 400 mmol / kg.
[11] The semen preservation solution according to any one of [1] to [10], further comprising a buffer.
[12] The semen preservation solution according to any one of [1] to [11], wherein the buffer is tris (hydroxymethyl) aminomethane or citric acid.
[13] The semen preservation solution according to any one of [2] to [12], wherein the mammal is a cow, buffalo, pig, goat, horse, or sheep.
[14] A semen-containing storage solution comprising the semen storage solution according to any one of [1] to [13], which contains semen.
[15] The semen-containing storage solution according to [14], wherein the semen is a semen obtained by thawing cryopreserved semen.
[16] A method for transporting semen, characterized in that the semen-containing preservative solution according to [14] is transported in contact with mineral oil.
[17] A method for transporting semen, characterized in that the semen-containing preservative solution according to [14] is brought into contact with a gas containing an inert gas and transported in a state where the oxygen volume ratio is 20.1% or less. .
[18] The semen transport method according to [17], wherein the inert gas is hydrogen gas, nitrogen gas, or argon gas.
本発明によれば、精子タンパク質の脱リン酸化阻害剤を用いることにより、保存後の精子運動性を高く維持できる。また、精子の運動性だけでなく、生存かつ先体正常精子率にも優れた人工授精用の精液を供給することができる。
本発明における精子運動性や生存性を維持するメカニズムとしては、脱リン酸化阻害といったタンパク質のリン酸化の制御により保存・輸送中の精子の代謝を抑えられることや、精子運動性や生存性に関わるタンパク質の特異的なリン酸化の制御により保存・輸送後、さらには凍結融解後の精子運動性を維持できるようになること、などが考えられる。
According to the present invention, sperm motility after storage can be maintained high by using a sperm protein dephosphorylation inhibitor. Moreover, not only sperm motility but also semen for artificial insemination that is excellent in survival and acrosome normal sperm rate can be supplied.
As a mechanism for maintaining sperm motility and viability in the present invention, it is possible to suppress metabolism of sperm during storage and transport by controlling protein phosphorylation such as dephosphorylation inhibition, and to relate to sperm motility and viability. It may be possible to maintain sperm motility after storage / transport and further freeze-thaw by controlling specific phosphorylation of proteins.
本発明は、タンパク質の脱リン酸化阻害剤を含有する精液用保存液、及びそれを用いた精液輸送方法に関する。 The present invention relates to a semen preservation solution containing a protein dephosphorylation inhibitor and a semen transport method using the same.
本発明において、保存又は輸送の対象とされる精液は、哺乳動物由来の精液を用いることができる。哺乳動物としては、ウシ、水牛、ブタ、ヤギ、ウマ、ヒツジ等の家畜動物、イヌ、ネコ、ウサギ等の愛玩動物、パンダ等の絶滅危惧動物、及び、マウス、ハムスター、ラット等の実験動物が挙げられる。本発明の精液用保存液は、哺乳動物以外に、鳥類や魚類の精子保存と精子輸送に用いることができる。 In the present invention, mammal-derived semen can be used as the semen to be stored or transported. Mammals include domestic animals such as cattle, buffalo, pigs, goats, horses and sheep, pets such as dogs, cats and rabbits, endangered animals such as pandas, and experimental animals such as mice, hamsters and rats. Can be mentioned. The semen preservation solution of the present invention can be used for sperm preservation and sperm transport in birds and fish, in addition to mammals.
本発明の脱リン酸化阻害剤は、精液中に含まれるタンパク質、特に精子タンパク質の脱リン酸化を阻害する化合物である。 The dephosphorylation inhibitor of the present invention is a compound that inhibits dephosphorylation of proteins contained in semen, particularly sperm proteins.
脱リン酸化が阻害される精子タンパク質としては、精子の運動性に関連するタンパク質である。好ましくは、SDS−PAGE(Sodium Dodecyl Sulfate-PolyAcrylamide Gel Electrophoresis)で求められる質量が50〜100キロダルトン(kDa)のタンパク質が挙げられる。特に、質量が55kDaのタンパク質、及び質量が77kDaのタンパク質が挙げられる。 A sperm protein whose dephosphorylation is inhibited is a protein associated with sperm motility. Preferably, a protein whose mass calculated | required by SDS-PAGE (Sodium Dodecyl Sulfate-PolyAcrylamide Gel Electrophoresis) is 50-100 kilodalton (kDa) is mentioned. In particular, a protein having a mass of 55 kDa and a protein having a mass of 77 kDa can be mentioned.
脱リン酸化阻害剤としては、酸性ホスファターゼ阻害剤、アルカリホスファターゼ阻害剤、チロシンホスファターゼ阻害剤等が挙げられる。脱リン酸化阻害剤である具体的化合物としては、イミダゾール、オルトバナジン酸ナトリウム、ピロリン酸二水素ナトリウム、βグリセロリン酸二ナトリウム、酒石酸ナトリウム、モリブデン酸ナトリウム、及びフッ化ナトリウムが好ましく、イミダゾール、フッ化ナトリウム、及びモリブデン酸ナトリウムがより好ましい。 Examples of dephosphorylation inhibitors include acid phosphatase inhibitors, alkaline phosphatase inhibitors, tyrosine phosphatase inhibitors and the like. Specific compounds that are dephosphorylation inhibitors are preferably imidazole, sodium orthovanadate, sodium dihydrogen pyrophosphate, disodium β-glycerophosphate, sodium tartrate, sodium molybdate, and sodium fluoride. Sodium and sodium molybdate are more preferred.
脱リン酸化阻害剤の含有量は、1〜100mMであることが好ましく、1〜20mMがより好ましく、4〜12mMが特に好ましい。
本発明の精子用保存液は、精子のエネルギー源として糖成分を含有しても良い。糖としては、グルコース、フルクトース、スクロース、ラクトース等に加えて、ラフィノース、フルクトオリゴ糖、イソマルトオリゴ糖、ゲンチオオリゴ糖、ガラクトオリゴ糖等の、オリゴ糖が挙げられる。
糖成分の濃度は、1〜150mMが好ましい。
The content of the dephosphorylation inhibitor is preferably 1 to 100 mM, more preferably 1 to 20 mM, and particularly preferably 4 to 12 mM.
The sperm preservation solution of the present invention may contain a sugar component as an energy source for sperm. Examples of the sugar include oligosaccharides such as raffinose, fructooligosaccharide, isomaltooligosaccharide, gentiooligosaccharide, and galactooligosaccharide, in addition to glucose, fructose, sucrose, lactose and the like.
The concentration of the sugar component is preferably 1 to 150 mM.
糖成分としてフルクトース又はラクトースを用いる場合は、フルクトースの濃度は1〜50mMが好ましく、5〜30mMがより好ましい。ラクトースの濃度は、1〜100mMが好ましく、20〜60mMがより好ましい。糖成分としてスクロース又はラクトースを用いる場合は、スクロースの濃度は10〜150mMが好ましく、30〜70mMがより好ましい、ラクトース濃度は10〜150mMが好ましく、30〜70mMがより好ましい。 When fructose or lactose is used as the sugar component, the concentration of fructose is preferably 1 to 50 mM, and more preferably 5 to 30 mM. The concentration of lactose is preferably 1 to 100 mM, and more preferably 20 to 60 mM. When sucrose or lactose is used as the sugar component, the sucrose concentration is preferably 10 to 150 mM, more preferably 30 to 70 mM, and the lactose concentration is preferably 10 to 150 mM, more preferably 30 to 70 mM.
糖成分として、オリゴ糖を用いる場合は、オリゴ糖の濃度は、20〜40g/L(w/v)が好ましく、25〜35g/L(w/v)がより好ましい。 When oligosaccharide is used as the sugar component, the concentration of oligosaccharide is preferably 20 to 40 g / L (w / v), more preferably 25 to 35 g / L (w / v).
本発明の精子用保存液の浸透圧は、精子の運動活性及び受精活性が維持できる浸透圧であれば任意の浸透圧であってもよいが、通常は230〜3414mmol/kgである(Guthrie et al.、Biology of Reproduction 67、 1811−1816 (2002))。浸透圧は、溶質の濃度、解離度等から理論値を計算することもできるが、溶液を構成する物質の相互作用等を考慮して、浸透圧計(オズモメーター)を用いて測定される。
本発明の精子用保存液の浸透圧は、230〜400mmol/kgが好ましく、250〜350mmol/kgがより好ましい。
The osmotic pressure of the sperm preservation solution of the present invention may be any osmotic pressure as long as the sperm motility and fertilization activities can be maintained, but is usually 230 to 3414 mmol / kg (Guthrie et al., Biology of Reproduction 67, 1811-1816 (2002)). The osmotic pressure can be calculated theoretically from the concentration of solute, the degree of dissociation, etc., but is measured using an osmometer (osmometer) in consideration of the interaction of substances constituting the solution.
The osmotic pressure of the sperm preservation solution of the present invention is preferably 230 to 400 mmol / kg, more preferably 250 to 350 mmol / kg.
本発明の精子用保存液は、所望のpHを達成するために緩衝剤を含んでもよい。緩衝剤としては、中性付近に緩衝作用を持つ緩衝剤であれば任意のものを選択することができ、トリス(ヒドロキシメチル)アミノメタン、メス、ヘペス、テス、トリシン等の緩衝剤、リン酸緩衝液、クエン酸緩衝液、酢酸緩衝液、炭酸緩衝液等が挙げられる。
緩衝剤としては、トリス(ヒドロキシメチル)アミノメタンが好ましい。
The sperm preservation solution of the present invention may contain a buffer to achieve the desired pH. As the buffer, any buffer can be selected as long as it has a buffering action near neutrality. Buffers such as tris (hydroxymethyl) aminomethane, female, hepes, tes, and tricine, phosphate Examples include a buffer solution, a citrate buffer solution, an acetate buffer solution, and a carbonate buffer solution.
As the buffer, tris (hydroxymethyl) aminomethane is preferred.
また、所望のpHに調整するため、酸若しくはアルカリを用いることができる。酸としては、塩酸、硫酸、リン酸、酢酸、クエン酸、ギ酸、グルコン酸、乳酸、シュウ酸、酒石酸、アスコルビン酸等が挙げられる。アルカリとしては、水酸化ナトリウム、水酸化カリウム、水酸化カルシウム、炭酸ナトリウム、炭酸水素ナトリウム、炭酸カリウム、炭酸水素カリウム等のアルカリ金属水酸化物等が挙げられる。 Moreover, in order to adjust to desired pH, an acid or an alkali can be used. Examples of the acid include hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, formic acid, gluconic acid, lactic acid, oxalic acid, tartaric acid, ascorbic acid and the like. Examples of the alkali include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, and potassium hydrogen carbonate.
緩衝剤として、トリス(ヒドロキシメチル)アミノメタン又はクエン酸を用いる場合は、トリス(ヒドロキシメチル)アミノメタンの濃度は、50〜200mMが好ましく、80〜150mMがより好ましい。クエン酸の濃度は、20〜80mMが好ましく、25〜60mMがより好ましい。
pH調整のための緩衝剤としては、クエン酸が好ましい。
When tris (hydroxymethyl) aminomethane or citric acid is used as the buffer, the concentration of tris (hydroxymethyl) aminomethane is preferably 50 to 200 mM, more preferably 80 to 150 mM. The concentration of citric acid is preferably 20 to 80 mM, and more preferably 25 to 60 mM.
As a buffer for adjusting pH, citric acid is preferable.
本発明の精液用保存液は、細菌の繁殖を防ぐために抗生物質を含んでもよい。含まれても良い。抗生物質としては、ペニシリン、ストレプトマイシン、ゲンタマイシン、タイロシン、リンコマイシン、スペクチノマイシン、ジベカシン等が挙げられる。 The semen preservation solution of the present invention may contain antibiotics to prevent bacterial growth. May be included. Antibiotics include penicillin, streptomycin, gentamicin, tylosin, lincomycin, spectinomycin, dibekacin and the like.
本発明の精液用保存液は、冷却ストレスから精子を保護するために大豆レシチンや卵黄を含んでもよい。一方、鳥インフルエンザ等の発生により家きん卵の流通が制限された場合や、自然災害等により種畜からの精液採取が可能な状況で製造施設が機能停止した場合に、その製造施設では精液の冷却保存ができなくなるため、冷却せずに精液を長期保存し、遠隔地に輸送することもできる。 The semen preservation solution of the present invention may contain soy lecithin or egg yolk in order to protect sperm from cooling stress. On the other hand, when the distribution of poultry eggs is restricted due to the occurrence of bird flu, etc., or when the production facility stops functioning in a situation where semen can be collected from breeding stock due to natural disasters, Since it cannot be stored, semen can be stored for a long time without cooling and transported to a remote location.
本発明の精液含有保存液は、精液を前記精液用保存液で希釈して得られる。精液の希釈倍率は、精子の生存性に影響を与えない限り特に限定されないが、1.5倍〜10倍希釈が好ましく、2〜4倍希釈がより好ましい。 The semen-containing storage solution of the present invention is obtained by diluting semen with the semen storage solution. The dilution factor of semen is not particularly limited as long as it does not affect the viability of sperm, but is preferably 1.5 times to 10 times, more preferably 2 to 4 times.
本発明の精液輸送方法は、精子の生存性に影響を与えない限り特に限定されないが、精液、又は精液含有保存液を、ミネラルオイルと又は不活性ガスを空気より多く含有する気体と接触させた状態で輸送することが好ましい。
ミネラルオイルは、精製されたパラフィン系であれば特に限定されないが、医療用軟膏基剤として用いられるものが好ましい。
不活性ガスとしては、水素ガス、窒素ガス、アルゴンガス等が挙げられる。
The semen transport method of the present invention is not particularly limited as long as it does not affect the viability of sperm, but semen or a semen-containing storage solution is brought into contact with mineral oil or a gas containing more inert gas than air. It is preferable to transport in a state.
The mineral oil is not particularly limited as long as it is a purified paraffinic one, but is preferably used as a medical ointment base.
Examples of the inert gas include hydrogen gas, nitrogen gas, and argon gas.
本発明の精液輸送方法で精液は、精液含有保存液及びミネラルオイル又は不活性ガスからなる2層構造の状態で輸送されることが好ましい。 In the semen transporting method of the present invention, semen is preferably transported in a two-layer structure comprising a semen-containing preservation solution and mineral oil or inert gas.
以下、実施例を挙げて、本発明を具体的に説明する。本発明はこれらに限定して解釈されるものではない。 Hereinafter, the present invention will be specifically described with reference to examples. The present invention is not construed as being limited to these.
<1.精液用保存液の調製>
下記表1記載の各物質を表1の組成になるように秤量し、蒸留水を加えて100mLにし、トリスクエン酸緩衝糖液(TC液)100mLを調製した。
<1. Preparation of stock solution for semen>
Each substance shown in the following Table 1 was weighed so as to have the composition shown in Table 1, and distilled water was added to 100 mL to prepare 100 mL of triskelic acid buffered sugar solution (TC solution).
上記TC液に、脱リン酸化阻害剤として、イミダゾール(和光純薬工業社製)、モリブデン酸ナトリウム(シグマアルドリッチ社製)、又はフッ化ナトリウム(和光純薬工業社製)を、0.1mM、1mM、又は10mMとなるように添加し、精液用保存液を調製した。 To the TC solution, 0.1 mM imidazole (manufactured by Wako Pure Chemical Industries), sodium molybdate (manufactured by Sigma Aldrich), or sodium fluoride (manufactured by Wako Pure Chemical Industries) as a dephosphorylation inhibitor, A stock solution for semen was prepared by adding 1 mM or 10 mM.
<2.精液含有保存液の調製>
5頭のホルスタイン種種雄牛(5〜9才、各1射精)から採取した新鮮精液1mLを、ポリエチレン製の丸底チューブ(コーニング社製)に入れた後、上記精液用保存液(25℃)1mLを加えて1:1の割合で希釈した(2倍希釈)。
得られた精液含有保存液を、水温を18℃に設定した卓上型振とう恒温槽(タイテック社製)を用いて振とう速度30 rpm で振とうしながら24時間保存した。
<2. Preparation of semen-containing stock solution>
1 mL of fresh semen collected from 5 Holstein bulls (5-9 years old, 1 ejaculation each) was placed in a polyethylene round bottom tube (Corning), and then the above semen preservation solution (25 ° C.) 1 mL was added and diluted at a ratio of 1: 1 (2-fold dilution).
The obtained semen-containing stock solution was stored for 24 hours while shaking at a shaking speed of 30 rpm using a desktop shaking thermostat (manufactured by Taitec Co., Ltd.) with a water temperature set at 18 ° C.
実施例1(精子運動率の測定)
直ちに全ての精液を冷却処理することができない場合や畜舎から遠隔地に高度な製造技術または高額な製造設備を持つ施設まで輸送する場合を想定し、24時間保存した後、TC液で精子濃度が約2000万/mLになるように精液含有保存液を希釈した。希釈精液を予め38℃に加温した厚さ20μmのスライドチャンバー(Leja社製)にマウントした後、精子運動解析システム(Ceros、Hamilton Thorne社製)により精子の運動性を解析し、運動精子率を測定した。
測定結果を図1〜3に示す。脱リン酸化阻害剤濃度依存的な運動精子率の向上が観察された。
Example 1 (Measurement of sperm motility)
Assuming that all the semen cannot be cooled immediately or transported from a barn to a facility with advanced manufacturing technology or expensive manufacturing equipment, store it for 24 hours, and then store the sperm concentration in the TC solution. The semen-containing stock solution was diluted to about 20 million / mL. After mounting the diluted semen on a slide chamber (Leja) with a thickness of 20μm preheated to 38 ° C, the sperm motility is analyzed by a sperm motility analysis system (Ceros, Hamilton Thorne) Was measured.
The measurement results are shown in FIGS. A dephosphorylation inhibitor concentration-dependent improvement in the rate of motile sperm was observed.
実施例2(凍結精液の、融解直後及び培養後の運動精子率)
[凍結精液の作製]
24時間保存後の精液を、TC液で2回洗浄した。洗浄した精液を、非特許文献1の310〜311頁に記載の方法で凍結し、培養試験を実施するまで液体窒素中で保存した。
[精液の融解、及び精子の培養]
凍結精液を38℃の温湯で15秒かけて融解した。融解した精液に含まれる精子を、特許文献1の実施例1に記載の精子洗浄液を用いて洗浄した。洗浄後に38℃で培養しながら、融解直後、培養0時間、3時間、6時間目に精子運動解析装置(CASA)で精子運動性を解析して運動精子率を測定した。
測定結果を図4〜6に示す。脱リン酸化阻害剤の添加によって、運動精子率が向上することが観察された。
Example 2 (Moving sperm rate immediately after thawing and after culturing of frozen semen)
[Preparation of frozen semen]
The semen stored for 24 hours was washed twice with TC solution. The washed semen was frozen by the method described on pages 310 to 311 of
[Semen thawing and sperm culture]
The frozen semen was thawed with hot water at 38 ° C. over 15 seconds. Sperm contained in the melted semen was washed using the sperm washing solution described in Example 1 of
The measurement results are shown in FIGS. It was observed that the addition of dephosphorylation inhibitors improved the rate of motile sperm.
実施例3(免疫染色を用いた、保存前後の精子チロシンリン酸化状態確認)
5頭のホルスタイン種種雄牛(5〜7才、各1射精)から精液を採取し、TC液で24時間保存された精液、及び保存前の精液を用いて、精子のチロシンリン酸化状態を確認した。
精液中の精子をリン酸緩衝生理食塩水(Phosphate buffered saline、PBS)で2回洗浄した。洗浄した精子を1%ホルムアルデヒド(和光純薬工業社製)-PBSにより15分間室温で固定し、200mMグリシン(和光純薬工業社製)を1mL加え反応停止させた。遠心分離により上清を除去し、PBSで2回洗浄することで、固定された精子を回収した。洗浄精子をスライドグラス(松浪硝子工業社製)に塗抹し風乾させた後、免疫染色に用いた。
Example 3 (Confirmation of sperm tyrosine phosphorylation state before and after storage using immunostaining)
Semen was collected from 5 Holstein bulls (5-7 years old, 1 ejaculation each), and sperm tyrosine phosphorylation status was confirmed using semen stored for 24 hours in TC solution and semen before storage did.
The sperm in the semen was washed twice with phosphate buffered saline (PBS). The washed sperm was fixed with 1% formaldehyde (Wako Pure Chemical Industries, Ltd.)-PBS for 15 minutes at room temperature, and 1 mL of 200 mM glycine (Wako Pure Chemical Industries, Ltd.) was added to stop the reaction. The supernatant was removed by centrifugation and washed with PBS twice to recover the fixed sperm. The washed sperm was smeared on a slide glass (manufactured by Matsunami Glass Kogyo Co., Ltd.), air-dried, and used for immunostaining.
塗抹した精子を0.1% Triton X-100 (SERVA Electrophoresis社製)-PBSにより室温で15分間処理し、3%BSA(和光純薬工業社製)-PBSで30分間ブロッキングした。PBSで1000倍希釈した抗チロシンリン酸化抗体(Clone 4G10; Merck社製)で1時間処理した。PBSで3回洗浄した後、300倍希釈したAlexa488標識抗マウスIgG抗体(Thermo Fisher Scientific社製)で1時間処理した。PBSで3回洗浄した後、カバーガラス(松浪硝子工業社製)をかけて正立蛍光顕微鏡システム(DM5500 B; Leica Microsystems社製)で観察した。
各個体100精子をカウントし、リン酸化チロシン(pY)陽性精子の内、精子中片部の蛍光強度が高い精子の数を比較した。
観察結果を図7に示す。
The smeared sperm was treated with 0.1% Triton X-100 (SERVA Electrophoresis) -PBS for 15 minutes at room temperature, and blocked with 3% BSA (Wako Pure Chemical Industries) -PBS for 30 minutes. It was treated with an anti-tyrosine phosphorylated antibody (Clone 4G10; manufactured by Merck) diluted 1000 times with PBS for 1 hour. After washing 3 times with PBS, it was treated with Alexa488-labeled anti-mouse IgG antibody (manufactured by Thermo Fisher Scientific) diluted 300 times for 1 hour. After washing with PBS three times, a cover glass (manufactured by Matsunami Glass Kogyo Co., Ltd.) was applied and observed with an upright fluorescent microscope system (DM5500 B; manufactured by Leica Microsystems).
100 sperm of each individual was counted, and the number of sperm having high fluorescence intensity in the middle part of the sperm among phosphorylated tyrosine (pY) positive sperm was compared.
The observation results are shown in FIG.
24時間保存後の精子は、リン酸化チロシン(pY)陽性シグナルの強度が減少する傾向を確認した。
保存中に、pYが脱リン酸化される精子が多くなったことから、脱リン酸化の阻害が精子運動性維持に寄与することが示唆された。
Sperm after storage for 24 hours confirmed a tendency for the intensity of the phosphorylated tyrosine (pY) positive signal to decrease.
During storage, the number of sperm from which pY was dephosphorylated increased, suggesting that inhibition of dephosphorylation contributes to maintenance of sperm motility.
実施例4(脱リン酸化阻害剤カクテルが保存後の精子生存率、先体正常性及び精子運動性におよぼす影響)
6頭のホルスタイン種種雄牛(7〜9才、各1射精)から精液を採取し、和光純薬工業社製のPhosphatase Inhibitor Cocktail Solution II(以下、脱リン酸化阻害剤カクテル)を脱リン酸化阻害剤として用いた点以外は、上記1及び2と同じ方法で精液用保存液を調製し、精液含有保存液を得た。得られた精液含有保存液を用いて、24時間保存後の精子生存かつ先体正常性、及び精子運動性を確認した。
Example 4 (Effect of Dephosphorylation Inhibitor Cocktail on Sperm Viability, Acrosome Normality, and Sperm Motility after Storage)
Semen was collected from 6 Holstein bulls (7-9 years old, 1 ejaculation each), and Phosphatase Inhibitor Cocktail Solution II (hereinafter dephosphorylation inhibitor cocktail) manufactured by Wako Pure Chemical Industries, Ltd. was inhibited from dephosphorylation. Except for the point used as an agent, a semen preservation solution was prepared in the same manner as in 1 and 2 above to obtain a semen-containing preservation solution. Using the obtained semen-containing storage solution, sperm survival, acrosome normality, and sperm motility after 24 hours storage were confirmed.
[生存かつ先体正常率の測定]
24時間保存後の精液から100万精子を分取し、特許文献1に記載の希釈液にFITC標識ピーナッツレクチン(Sigma社製、PNA)及びヨウ化プロピディウム(Sigma社製、PI)をそれぞれ2μg/mLとなるように溶かした溶液を用いて、10分間25℃の条件で二重染色した。染色後、セルアナライザー(Quanta SC; Beckman Coulter社製)で非染色精子を生存かつ先体正常精子としてカウントし、その百分率を算出し、生存かつ先体正常率の測定を測定した。
測定結果を図8に示す。
脱リン酸化阻害剤カクテルを含まない保存液で保存した対照区と比較して、脱リン酸化阻害剤カクテルを含む精液用保存液で保存すると、精子の生存かつ先体正常率が向上した。
[運動精子率の測定]
24時間保存後の精液を、TC液で精子濃度が約2000万/mLになるように希釈した。希釈精液を予め38℃に加温した厚さ20μmのスライドチャンバー(Leja社製)にマウントした後、精子運動解析システム(Ceros、Hamilton Thorne社製)により精子運動性を解析して、運動精子率を測定した。
測定結果を図8に示す。
[Measurement of survival and acrosome normality]
One million spermatozoa were collected from the semen stored for 24 hours, and FITC-labeled peanut lectin (Sigma, PNA) and propidium iodide (Sigma, PI) were each 2 μg / ml in the diluent described in
The measurement results are shown in FIG.
Sperm survival and acrosome prevalence were improved when stored in a semen stock containing a dephosphorylation inhibitor cocktail compared to a control stored in a stock containing no dephosphorylation inhibitor cocktail.
[Measurement of motor sperm rate]
The semen after storage for 24 hours was diluted with a TC solution so that the sperm concentration was about 20 million / mL. Mount the diluted semen on a slide chamber (Leja) with a thickness of 20μm preheated to 38 ° C, then analyze the sperm motility with a sperm motility analysis system (Ceros, Hamilton Thorne) Was measured.
The measurement results are shown in FIG.
脱リン酸化阻害剤カクテルを含まない保存液で保存した対照区と比較して、脱リン酸化阻害剤カクテルを含む精液用保存液で保存すると、精子の運動性が向上した。 Sperm motility was improved when stored in a semen stock containing a dephosphorylation inhibitor cocktail as compared to a control stored in a stock containing no dephosphorylation inhibitor cocktail.
[保存後の精液を凍結・融解した後の運動精子率及び精子平均経路速度]
実施例1記載の方法で24時間保存後の精液を凍結・融解した後、0〜6時間培養して、運動精子率及び平均経路速度を測定した。
運動精子率及び平均経路速度は家畜精液の品質の指標であり、高い値であれば、製品の合格可能性が高いことを示す。
測定結果を図9に示す。
脱リン酸化阻害剤カクテルを含まない保存液で保存した対照区と比較して、脱リン酸化阻害剤カクテルを含む精液用保存液で保存すると、凍結・融解した後の精子運動性が向上した。
[Moving sperm rate and average sperm speed after freezing and thawing semen after storage]
After freezing and thawing the semen stored for 24 hours by the method described in Example 1, it was cultured for 0 to 6 hours, and the rate of motile spermatozoa and the average pathway speed were measured.
Motility sperm rate and average path velocity are indicators of livestock semen quality, and high values indicate that the product is likely to pass.
The measurement results are shown in FIG.
Sperm motility after freezing and thawing improved when stored in a semen storage solution containing a dephosphorylation inhibitor cocktail, compared to a control group stored in a storage solution without a dephosphorylation inhibitor cocktail.
実施例5(イミダゾールが保存後の精子運動性、精子生存性に及ぼす影響)
イミダゾールを0、2、4、6、8、又は10mMとなるように添加した点以外は、上記1及び2と同じ方法で精液用保存液を調製し、精液含有保存液を得た。得られた精液含有保存液を用いて、24時間保存後の精子運動性を測定した。
測定結果を図10(n=14)に示す。
運動精子率は、イミダゾール濃度依存的に高まり、イミダゾール濃度10mMにおいて最も高かった。
また、イミダゾールを含まない精液用保存液を用いて保存した対照区(0mM)と比較して、10mMのイミダゾールを含む精液用保存液を用いて保存した試験区は、運動精子率が高かった(図1)。
Example 5 (Influence of imidazole on sperm motility and sperm viability after storage)
A semen-containing stock solution was prepared in the same manner as in 1 and 2 above except that imidazole was added to 0, 2, 4, 6, 8, or 10 mM to obtain a semen-containing stock solution. Using the obtained semen-containing storage solution, sperm motility after storage for 24 hours was measured.
The measurement results are shown in FIG. 10 (n = 14).
Motile sperm rate increased in an imidazole concentration-dependent manner and was highest at an imidazole concentration of 10 mM.
Moreover, compared with the control group (0 mM) preserve | saved using the semen preservation solution which does not contain imidazole, the test group preserve | saved using the semen preservation solution containing 10 mM imidazole had a high motor sperm rate ( FIG. 1).
さらに、精子のチロシンリン酸化状態に及ぼす影響について確認するために、10mMのイミダゾールを含む精液用保存液を用いて保存した精子を、ウエスタンブロット法によりリン酸化チロシン酸化状態を比較した。その結果、77キロダルトン(kDa)付近及び55kDa付近のバンドの発光強度が試験区で高かった(図11、n=8)。図11において、「当日」は保存前の精液を用いた場合の結果を示す。
この結果は、イミダゾールが、77kDa付近及び55kDa付近のタンパク質のチロシン脱リン酸化を阻害していることを示唆する。
Furthermore, in order to confirm the influence of sperm on the tyrosine phosphorylation state, sperm preserved using a semen preservation solution containing 10 mM imidazole was compared in phosphorylated tyrosine oxidation state by Western blotting. As a result, the emission intensity of bands near 77 kilodalton (kDa) and 55 kDa was high in the test section (FIG. 11, n = 8). In FIG. 11, “on the day” indicates the result when the semen before storage is used.
This result suggests that imidazole inhibits tyrosine dephosphorylation of proteins around 77 kDa and 55 kDa.
なお、ウエスタンブロットは、以下の手順で行った。
1.保存前及び保存後の精液をPBSで2回洗浄し、4x Laemmli Sample Buffer(200mM トリス、8%SDS、24%β-メルカプトエタノール、40%グリセロール、1%ブロモフェノールブルー)で希釈し、95℃で5分間熱処理を行った。
2.SDS−PAGEは、電気泳動用プレキャストゲル(ミニプロティアンTGXゲル4-20%、Biorad社製)を用い、100∨で1時間半電気泳動した。
3.その後、PVDF膜への転写(ミニトランスブロットセル、Biorad社製)を100∨で1時間行った。転写したPVDF膜を3%BSA添加TBS−T(25mMトリス、150mM 塩化ナトリウム、0.1% Tween 20、pH7.6)に室温で1時間処理してブロッキング反応を行った。
4.続いて、1次抗体の反応を4℃、オーバーナイトで行った。1次抗体は抗リン酸化チロシン抗体(Clone 4G10; Merck社製)を用いた。
5.TBS−Tで洗浄後、2次抗体の反応を1時間、室温で行った。2次抗体は、1次抗体の動物種のHRP標識抗体(Jackson ImmunoResearch)をTBS−Tで希釈して用いた。処理したPVDF膜はTBS−Tで洗浄した後、ECL prime(GE lifescience社製)を用いて発光反応を行い、ケミルミ撮影装置(MultiImager II; Bio tools Inc.製)を用いて検出した。
6.得られた77kDa付近及び55kDa付近のバンドの発光強度を画像処理ソフトウェア(ImageJ、アメリカ国立衛生研究所)を用いて測定し、対照区及び試験区の「当日」に対する相対値を比較した。
The Western blot was performed according to the following procedure.
1. Semen before and after storage was washed twice with PBS, diluted with 4x Laemmli Sample Buffer (200 mM Tris, 8% SDS, 24% β-mercaptoethanol, 40% glycerol, 1% bromophenol blue) at 95 ° C For 5 minutes.
2. For SDS-PAGE, electrophoresis was performed for 1 hour and a half at 100 mm using a precast gel for electrophoresis (Miniprotian TGX gel 4-20%, manufactured by Biorad).
3. Thereafter, transcription onto a PVDF membrane (minitrans blot cell, manufactured by Biorad) was performed at 100 mm for 1 hour. The transferred PVDF membrane was treated with 3% BSA-added TBS-T (25 mM Tris, 150 mM sodium chloride, 0.1
4). Subsequently, the primary antibody reaction was performed at 4 ° C. overnight. As the primary antibody, an anti-phosphotyrosine antibody (Clone 4G10; manufactured by Merck) was used.
5. After washing with TBS-T, the secondary antibody reaction was carried out for 1 hour at room temperature. As the secondary antibody, an HRP-labeled antibody (Jackson ImmunoResearch) of an animal species of the primary antibody was diluted with TBS-T. The treated PVDF membrane was washed with TBS-T, then subjected to a luminescence reaction using ECL prime (manufactured by GE lifescience), and detected using a chemirmi imaging apparatus (MultiImager II; manufactured by Bio tools Inc.).
6). Luminescence intensity of the obtained bands around 77 kDa and 55 kDa was measured using image processing software (ImageJ, National Institutes of Health, USA), and the relative values of the control group and the test group with respect to “the same day” were compared.
実施例6(ミネラルオイルが、精液保存後の精子運動性に及ぼす影響)
6頭のホルスタイン種種雄牛(5〜9才、各1射精)から採取した精液2mLを、ポリスチレン製の丸底チューブ(コーニング社製)に分注し、TC液2mLを加えて1:1の割合で希釈した(2倍希釈)。
その後、丸底チューブ内の精液含有保存液以外の空間(空気層)にミネラルオイル(D05042; 吉田製薬社製)を満たし密閉した。密閉したチューブを、温度を18℃に設定したクロマトグラフィー冷蔵庫(REC-5004; Revco社製)内に設置した振とう機(NR-30; タイテック社製)の上に、チューブをその長辺に対して平行に振とうできるように設置し、振とう速度120rpmで振とうしながら24時間保存した。
Example 6 (Effect of mineral oil on sperm motility after semen storage)
2 mL of semen collected from 6 Holstein bulls (5-9 years old, 1 ejaculation each) was dispensed into a round bottom tube made of polystyrene (manufactured by Corning), and 2 mL of TC solution was added to make 1: 1 Diluted in proportion (2-fold dilution).
Thereafter, the space (air layer) other than the semen-containing storage solution in the round bottom tube was filled with mineral oil (D05042; manufactured by Yoshida Pharmaceutical) and sealed. Place the sealed tube on its long side on a shaker (NR-30; manufactured by Taitec) installed in a chromatography refrigerator (REC-5004; manufactured by Revco) set at a temperature of 18 ° C. It was installed so that it could be shaken in parallel, and stored for 24 hours while shaking at a shaking speed of 120 rpm.
24時間保存後の精液を、実施例1記載の方法で凍結・融解した。融解直後、培養0時間、3時間、6時間目に精子運動解析装置(CASA)で精子運動性を解析して運動精子率及び平均経路速度を測定した。
測定結果を図12に示す。
空気層のミネラルオイルを満たして密閉した状態で保存すると、保存後に作製した凍結精液の融解後の精子運動性向上が観察された。
The semen after storage for 24 hours was frozen and thawed by the method described in Example 1. Immediately after thawing, sperm motility was analyzed with a sperm motility analyzer (CASA) at 0 hours, 3 hours, and 6 hours of culture, and the motility sperm rate and average path velocity were measured.
The measurement results are shown in FIG.
When stored in a sealed state filled with mineral oil in the air layer, an improvement in sperm motility after thawing of frozen semen prepared after storage was observed.
実施例7(ガスの充填が、精液保存後の精子運動性に及ぼす影響)
5頭のホルスタイン種種雄牛(5〜9才、各1射精)から採取した精液1mLを、ポリスチレン製の丸底チューブ(コーニング社製)に分注し、TC液1mLを加えて1:1の割合で希釈した(2倍希釈)。
その後、丸底チューブ内の精液含有保存液以外の空間(空気層)に、大陽日酸社製のガススプレー缶を用いて、精製空気、水素ガス、窒素ガス、アルゴンガス又は酸素ガスを充填し、直ちに密閉した。密閉したチューブを、18℃に設定したクロマトグラフィー冷蔵庫(REC-5004; Revco社製)内に設置した振とう機(NR-30; タイテック社製)の上に、チューブをその長辺に対して平行に振とうできるように設置し、振とう速度120rpmで振とうしながら24時間保存した。
Example 7 (Effect of gas filling on sperm motility after semen storage)
1 mL of semen collected from 5 Holstein bulls (5-9 years old, 1 ejaculation each) was dispensed into a round bottom tube made of polystyrene (manufactured by Corning), and 1 mL of TC solution was added to make 1: 1 Diluted in proportion (2-fold dilution).
After that, the space (air layer) other than the semen-containing preservative in the round bottom tube is filled with purified air, hydrogen gas, nitrogen gas, argon gas or oxygen gas using a gas spray can made by Taiyo Nippon Sanso And immediately sealed. Place the sealed tube on its long side on a shaker (NR-30; manufactured by Taitec) installed in a chromatography refrigerator (REC-5004; manufactured by Revco) set at 18 ° C. It was installed so that it could be shaken in parallel, and stored for 24 hours while shaking at a shaking speed of 120 rpm.
24時間保存後の精子運動性を、実施例1記載の方法で測定した結果を図13に示す(n=5)。
空気層に酸素ガスを充填して24時間保存すると、保存後の精子運動性が低下することが観察された。
空気層にアルゴンガス、水素ガス、窒素ガス、又はアルゴンガスを充填して24時間保存すると、保存後の精子運動性が、精製空気を充填した場合と比較して向上することが観察された。
The results of measuring sperm motility after storage for 24 hours by the method described in Example 1 are shown in FIG. 13 (n = 5).
It was observed that when the air layer was filled with oxygen gas and stored for 24 hours, the sperm motility after storage decreased.
When the air layer was filled with argon gas, hydrogen gas, nitrogen gas, or argon gas and stored for 24 hours, it was observed that the sperm motility after storage was improved as compared with the case of filling with purified air.
24時間保存後の精液を、実施例1記載の方法で凍結・融解した。融解直後、培養0時間、3時間、6時間目に精子運動解析装置(CASA)で精子運動性を解析して運動精子率及び平均経路速度を測定した。
測定結果を図14(n=5)に示す。
空気層に酸素ガスを充填して24時間保存すると、保存後に作製した凍結精子を融解した後の精子運動性及び運動性維持率が共に低下することが観察された。
空気層にアルゴンガス、水素ガス、窒素ガス、又はアルゴンガスを充填して24時間保存すると、保存後に作製した凍結精子を融解した後の精子運動性及び運動性維持率が、精製空気を充填した場合と比較して向上することが観察された。
The semen after storage for 24 hours was frozen and thawed by the method described in Example 1. Immediately after thawing, sperm motility was analyzed with a sperm motility analyzer (CASA) at 0 hours, 3 hours, and 6 hours of culture, and the motility sperm rate and average path velocity were measured.
The measurement results are shown in FIG. 14 (n = 5).
It was observed that when the air layer was filled with oxygen gas and stored for 24 hours, both the sperm motility and the motility maintenance rate after thawing the frozen sperm produced after storage were reduced.
When the air layer was filled with argon gas, hydrogen gas, nitrogen gas, or argon gas and stored for 24 hours, the sperm motility and motility maintenance rate after thawing the frozen sperm produced after storage was filled with purified air. An improvement was observed compared to the case.
実施例8(イミダゾールの添加及び窒素ガス充填の併用が保存後の精子運動性に及ぼす影響)
8頭のホルスタイン種種雄牛(5〜9才、各1射精)から採取した精液1mLを、ポリスチレン製の丸底チューブ(コーニング社製)に分注し、TC液又は10mMのイミダゾールを含む精液用保存液1mLを加えて1:1の割合で希釈した(2倍希釈)。
その後、丸底チューブ内の精液含有保存液以外の空間(空気層)に、大陽日酸社製のガススプレー缶を用いて、精製空気又は窒素ガスを充填し、直ちに密閉した。密閉したチューブを、18℃に設定したクロマトグラフィー冷蔵庫(REC-5004; Revco社製)内に設置した振とう機(NR-30; タイテック社製)の上に、チューブをその長辺に対して平行に振とうできるように設置し、振とう速度120rpmで振とうしながら24時間保存した。
Example 8 (Influence of combined use of imidazole and nitrogen gas filling on sperm motility after storage)
1 mL of semen collected from 8 Holstein bulls (5-9 years old, 1 ejaculation each) is dispensed to a round bottom tube made of polystyrene (manufactured by Corning) for semen containing TC solution or 10
Thereafter, the space (air layer) other than the semen-containing preservative solution in the round bottom tube was filled with purified air or nitrogen gas using a gas spray can made by Taiyo Nippon Sanso and immediately sealed. Place the sealed tube on its long side on a shaker (NR-30; manufactured by Taitec) installed in a chromatography refrigerator (REC-5004; manufactured by Revco) set at 18 ° C. It was installed so that it could be shaken in parallel, and stored for 24 hours while shaking at a shaking speed of 120 rpm.
24時間保存後の精子運動性を、実施例1記載の方法で測定した結果を図15のAに示す。「対照」はTC液で希釈してから精製空気を充填させて密閉・保存したものであり、「イミダゾール」は10mMのイミダゾールを含む精液用保存液で希釈してから精製空気を充填させて密閉・保存したものであり、「窒素ガス」はTC液で希釈してから窒素ガスを充填させて密閉・保存したものであり、「併用」は10mMのイミダゾールを含む精液用保存液で希釈してから窒素ガスを充填させて密閉・保存したものである。 The result of measuring the sperm motility after storage for 24 hours by the method described in Example 1 is shown in FIG. “Control” is diluted with TC solution and filled with purified air and sealed and stored. “Imidazole” is diluted with stock solution for semen containing 10 mM imidazole and then filled with purified air and sealed. -Stored, "Nitrogen gas" is diluted with TC solution, filled with nitrogen gas, sealed and stored, "Combination" is diluted with semen storage solution containing 10 mM imidazole And then filled and sealed with nitrogen gas.
10mMのイミダゾールを含む精液用保存液を用いて精液を希釈して、空気層に窒素ガスを充填して24時間保存した後の運動精子率は、それぞれ単独で処理した場合と比べて高かった。
24時間保存後の精液を、実施例1記載の方法で凍結・融解した。融解直後、培養0時間、3時間、6時間目に精子運動解析装置(CASA)で精子運動性を解析して運動精子率及び平均経路速度を測定した。
測定結果を図15のBに示す。
24時間保存後に精子洗浄して凍結保存した場合、融解後の培養中の運動精子率は併用区が最も高く推移した。
The percentage of motile spermatozoa after diluting semen with a semen preservation solution containing 10 mM imidazole, filling the air layer with nitrogen gas and storing for 24 hours was higher than when each was treated alone.
The semen after storage for 24 hours was frozen and thawed by the method described in Example 1. Immediately after thawing, sperm motility was analyzed with a sperm motility analyzer (CASA) at 0 hours, 3 hours, and 6 hours of culture, and the motility sperm rate and average path velocity were measured.
The measurement results are shown in FIG.
When the sperm was washed and stored frozen after 24 hours of storage, the motile sperm rate during culturing after thawing was highest in the combination group.
実施例9(イミダゾールの添加及び窒素ガス充填の併用が宅配便による運搬後の精子運動性に及ぼす影響)
盛岡種雄牛センター(盛岡市)に繋養される4頭のホルスタイン種種雄牛(5〜9才、各2射精)から採取した精液2mLを、ポリスチレン製の丸底チューブ(コーニング社製)に分注し、TC液又は10mMのイミダゾールを含む精液用保存液2mLを加えて1:1の割合で希釈した(2倍希釈)。
丸底チューブをさらに50mLのコニカルチューブ(コーニング社製)に入れ密閉し、水温18℃に調整した魔法瓶(MWO-K150; タイガー魔法瓶社製)に入れた。魔法瓶は発泡スチロールに梱包し、宅配便により家畜改良技術研究所(前橋市)に運搬した(運搬距離は約600km)。
運搬後の精子運動性を、実施例1記載の方法で測定した結果を図16のAに示す。
Example 9 (Influence of combined use of imidazole and nitrogen gas filling on sperm motility after delivery by courier)
The round bottom tube was further sealed in a 50 mL conical tube (Corning) and placed in a thermos (MWO-K150; Tiger Thermos) adjusted to a water temperature of 18 ° C. The thermos was packed in polystyrene foam and transported to the Livestock Improvement Technology Laboratory (Maebashi City) by courier (transport distance was about 600 km).
The result of having measured the sperm motility after conveyance by the method of Example 1 is shown to A of FIG.
試験区は、対照区と比較して運動精子率が高かった。
運搬後の精液を、実施例1記載の方法で凍結・融解した。融解直後、培養0時間、3時間、6時間目に精子運動解析装置(CASA)で精子運動性を解析して運動精子率を測定した。
測定結果を図16のBに示す。
試験区は、対照区と比較して培養中の運動精子率が高く推移した。
The test group had a higher rate of motor sperm compared to the control group.
The semen after transportation was frozen and thawed by the method described in Example 1. Immediately after thawing, sperm motility was analyzed with a sperm motility analyzer (CASA) at 0 hours, 3 hours, and 6 hours of culture, and the rate of motility was measured.
The measurement results are shown in FIG.
The test group showed a higher rate of motile spermatozoa during culture than the control group.
本発明の精液用保存液を用いて精液を保存すると、精子の運動性を高い水準で維持することが出来るため、遠隔地に存在する施設に高品質の精液を輸送することが可能となる。 When semen is stored using the semen preservation solution of the present invention, motility of sperm can be maintained at a high level, so that high-quality semen can be transported to facilities located in remote locations.
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018033638A JP6838232B2 (en) | 2018-02-27 | 2018-02-27 | Preservative solution for semen and semen transportation method using it |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018033638A JP6838232B2 (en) | 2018-02-27 | 2018-02-27 | Preservative solution for semen and semen transportation method using it |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019147764A true JP2019147764A (en) | 2019-09-05 |
JP6838232B2 JP6838232B2 (en) | 2021-03-03 |
Family
ID=67849115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018033638A Active JP6838232B2 (en) | 2018-02-27 | 2018-02-27 | Preservative solution for semen and semen transportation method using it |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6838232B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114586771A (en) * | 2022-03-16 | 2022-06-07 | 上海市农业科学院 | Cryopreservation method of pig semen |
-
2018
- 2018-02-27 JP JP2018033638A patent/JP6838232B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114586771A (en) * | 2022-03-16 | 2022-06-07 | 上海市农业科学院 | Cryopreservation method of pig semen |
Also Published As
Publication number | Publication date |
---|---|
JP6838232B2 (en) | 2021-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yeste | State-of-the-art of boar sperm preservation in liquid and frozen state | |
JP6932893B2 (en) | Diluted solution for sperm and storage method of sperm using it | |
Andrabi | Factors affecting the quality of cryopreserved buffalo (Bubalus bubalis) bull spermatozoa | |
Juyena et al. | Seminal plasma: an essential attribute to spermatozoa | |
Vishwanath et al. | Storage of bovine semen in liquid and frozen state | |
JP5835853B2 (en) | Aqueous solution for cell preservation | |
Campbell et al. | Restoration of ovarian function and natural fertility following the cryopreservation and autotransplantation of whole adult sheep ovaries | |
Mehdipour et al. | Effect of egg yolk plasma and soybean lecithin on rooster frozen-thawed sperm quality and fertility | |
US20220031813A1 (en) | Inhibitor of extracellular trap formation in leukocytes | |
Morrell et al. | Reproduction biotechnologies in germplasm banking of livestock species: a review | |
KR20020075373A (en) | Method of cryopreserving selected sperm cells | |
Santos et al. | Current and alternative trends in antibacterial agents used in mammalian semen technology | |
Waheed et al. | Evaluation of duck egg yolk for the cryopreservation of Nili-Ravi buffalo bull semen | |
Rahman et al. | Effect of skim milk and tris-citrate extenders to preserve the semen of indigenous ram of Bangladesh | |
JP6838232B2 (en) | Preservative solution for semen and semen transportation method using it | |
Lone et al. | Effect of Different Egg Yolk‐Based Extenders on the Quality of Ovine Cauda Epididymal Spermatozoa during Storage at 4° C | |
JP2015171346A (en) | Sperm diluent and sperm storage method using the same | |
KR102226182B1 (en) | Composition for cryopreservating sperm comprising egg yolk extract and milk protein extract | |
Czarny et al. | Acrosomal integrity, viability, and DNA damage of sperm from dasyurid marsupials after freezing or freeze drying | |
Xu et al. | Liquid storage of goat semen in chemically defined extenders | |
Goericke-Pesch et al. | Effect of seminal plasma vesicular structures in canine frozen-thawed semen | |
JP5738314B2 (en) | Artificial insemination straw | |
Dungdung et al. | Sperm motility regulatory proteins: a tool to enhance sperm quality | |
Mohamed et al. | The possibility of using citric phosphate dextrose in chilling ram semen instead of egg yolk and soybean lecithin to improve fertility | |
Trout | Evaluation of different concentrations of egg yolk in canine frozen semen extender |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190308 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200331 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200623 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200720 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201130 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210112 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210114 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6838232 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |